Section Arrow
KYMR.NASDAQ
- Kymera Therapeutics
Quotes are at least 15-min delayed:2024/10/31 18:56 EDT
Last
 46.2
-1.47 (-3.08%)
Day High 
46.98 
Prev. Close
47.67 
1-M High
50.29 
Volume 
747.82K 
Bid
18.42
Ask
51
Day Low
42.62 
Open
44.75 
1-M Low
41.61 
Market Cap 
3.08B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 47.83 
20-SMA 46.08 
50-SMA 47.06 
52-W High 53.27 
52-W Low 13.845 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.41/-2.87
Enterprise Value
3.16B
Balance Sheet
Book Value Per Share
10.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
78.59M
Operating Revenue Per Share
0.76
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.